Comparative Pharmacology
Head-to-head clinical analysis: METRETON versus METRO I V IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRETON versus METRO I V IN PLASTIC CONTAINER.
METRETON vs METRO I.V. IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine and mast cell stabilizer. Competitively inhibits histamine at H1 receptors and prevents release of histamine and other mediators from mast cells.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
1-2 mg/kg intramuscularly or intravenously every 6-8 hours as needed; maximum 100 mg per dose.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
None Documented
None Documented
Terminal elimination half-life is 24-36 hours; increased in renal impairment (up to 60 hours in anuria)
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Renal (80-90% as unchanged drug and metabolites), biliary/fecal (10-20%)
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)